• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

UGT1A3 Gene Record

  • Summary
  • Interactions
  • Claims
  • UGT1A3 54659 Druggable Genome

    Alternate Names:

    54659
    UDP GLUCURONOSYLTRANSFERASE FAMILY 1 MEMBER A3
    UGT1A3
    UDPGT
    UDPGT 1-3
    UGT-1C
    UGT1-03
    UGT1.3
    UGT1A3S
    UGT1C
    606428
    12535
    ENSG00000243135
    OTTHUMG00000059118
    PA37178
    ENSG00000288702
    UDP-glucuronosyltransferase 1-3
    P35503

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (0 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME
    ENZYME

    Publications:

    Lankisch TO et al., 2006, Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype., Hepatology
    Cho SK et al., 2012, The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers., Pharmacogenet Genomics
    Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol
    Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
    Carroll MB et al., 2017, Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose., Rheumatol Int
    Allegra S et al., 2019, The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients., Pharmacogenomics J
    Allegra S et al., 2017, Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients., Pharmacogenomics
    Allegra S et al., 2016, Deferasirox AUC efficacy cutoff and role of pharmacogenetics., Eur J Clin Pharmacol
    Cusato J et al., 2016, Role of pharmacogenetics on deferasirox AUC and efficacy., Pharmacogenomics
    Hirvensalo P et al., 2018, Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics., Clin Pharmacol Ther
  • DEFERASIROX   UGT1A3

    Interaction Score: 2.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30651574 28346059 27193993 27043265


    Sources:
    PharmGKB

  • ATAZANAVIR   UGT1A3

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17058217


    Sources:
    PharmGKB

  • FEBUXOSTAT   UGT1A3

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27798726


    Sources:
    PharmGKB

  • MONTELUKAST   UGT1A3

    Interaction Score: 0.49

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28940478


    Sources:
    PharmGKB

  • RITONAVIR   UGT1A3

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17058217


    Sources:
    PharmGKB

  • ALLOPURINOL   UGT1A3

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27798726


    Sources:
    PharmGKB

  • IBUPROFEN   UGT1A3

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25502615


    Sources:
    PharmGKB

  • FLUVASTATIN   UGT1A3

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • 7-ETHYL-10-HYDROXYCAMPTOTHECIN   UGT1A3

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATORVASTATIN   UGT1A3

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22555810


    Sources:
    PharmGKB

  • LOVASTATIN   UGT1A3

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SIMVASTATIN   UGT1A3

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • METHOTREXATE   UGT1A3

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29791011


    Sources:
    PharmGKB

  • RISPERIDONE   UGT1A3

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • Ensembl: ENSG00000243135

    • Version: 101_38

    Alternate Names:
    UGT1A3 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • PharmGKB: UGT1A3

    • Version: 18-August-2020

    Alternate Names:
    PA37178 PharmGKB ID

    Gene Info:

    Publications:
    Cho SK et al., 2012, The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers., Pharmacogenet Genomics
    Hirvensalo P et al., 2018, Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics., Clin Pharmacol Ther
    Wang Z et al., 2014, Human UGT1A4 and UGT1A3 conjugate 25-hydroxyvitamin D3: metabolite structure, kinetics, inducibility, and interindividual variability., Endocrinology

  • HingoraniCasas: ENSG00000243135

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000243135 Gene Symbol
    UGT1A3 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • Pharos: UGT1A3

    • Version: 01-February-2022

    Alternate Names:
    UDP-glucuronosyltransferase 1-3 Gene Name
    P35503 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21